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Background: Screening for depressive disorders in the general adult population is recommended, however, it is
unclear which instruments combine user friendliness and diagnostic utility. We evaluated the test performance of a
yes/no single item screener for depressive disorders (“Have you felt depressed or sad much of the time in the past
year?”) in comparison to the depressive disorder module of the Patient Health Questionnaire (PHQ-9).
Methods: Data from 3184 participants of the population-based KORA F3 survey in Augsburg/ Germany were used
to analyse sensitivity, specificity, ROC area, positive likelihood ratio (LR+), negative likelihood ratio (LR-), positive
predictive value (PPV), and negative predictive value (NPV) of the single item screener in comparison with “depressive
mood” and “major depressive disorder” defined according to PHQ-9 (both interviewer-administered versions).
Results: In comparison to PHQ-9 “depressive mood”, sensitivity was low (46%) with an excellent specificity (94%), (PPV
76%; NPV 82%; LR + 8.04; LR- .572, ROC area .702). When using the more conservative definition for “major depressive
disorder”, sensitivity increased to 83% with a specificity of 88%. The PPV under the conservative definition was low (32%),
but NPV was 99% (LR + 6.65; LR- .196; ROC area .852). Results varied across age groups and between males and females.
Conclusions: The single item screener is able to moderately decrease post-test probability of major depressive disorders
and to identify populations that should undergo additional, more detailed evaluation for depression. It may have limited
utility in combination with additional screening tests or for selection of at-risk populations, but cannot be recommended
for routine use as a screening tool in clinical practice.Background
Depressive disorders are a major burden for the health-
care systems worldwide leading to loss of productivity,
functional decline, and increased mortality [1-6]. The daily
functioning and overall health of patients with depression
can be improved when patients receive appropriate therap-
ies [7,8]. Screening alone does not improve the health of
patients with undiagnosed depressive disorders [9-12] but
screening combined with patient-support programs, such
as regular nurse follow-ups and close monitoring of adher-
ence to therapy, seems to be useful [13]. Therefore, the U.S.
Preventive Services Task Force recommends screening for* Correspondence: e.blozik@uke.de
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reproduction in any medium, provided the ordepressive disorders in the general adult population when
there are staff-assisted depression care supports in place
to assure accurate diagnosis, effective treatment, and
follow-up [14]. Additionally, screening for depressive dis-
orders is recommended in populations at risk such as
those with a family or personal history of depressive dis-
orders, multiple medical problems, unexplained physical
symptoms, chronic pain, or use of medical services that is
more frequent than expected even if no depression care
supports are available [15].
For screening purposes, different instruments exist [16].
Administering and evaluating comparatively long screening
instruments can be time-consuming and it may thus be
difficult to implement them in busy clinical settings [17].
Simple tests focusing explicitly on depressive disorders and
without the need for additional computation on the clini-
cian’s side seem to have the highest probability that this in-
formation is integrated into the clinical decision-makingtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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evaluations long instruments may increase respondent bur-
den [19]. This is why research teams searching for the
shortest possible measure proposed and evaluated screeners
consisting of one or two items [20]. Williams et al. pre-
sented a simple and easy-to-administer single item question
(“Have you felt depressed or sad much of the time in the
past year?”) and reported good sensitivity and less specifi-
city as compared to the Center for Epidemiologic Studies
Depression Screen (CES-D) [21] using a diagnostic SCID
interview (Structured Clinical Interview for Diagnostic and
Statistical Manual of Mental Disorders) as the criterion
(85% vs 88% and 66% vs 75%, respectively) [11]. In contrast,
Corson et al. found this single item to be specific (88%) but
less sensitive (78%) when using the 9-item Patient Health
Questionnaire (PHQ-9) [22] algorithm for major depres-
sion as the reference standard [20].
Given these discrepancies and given the fact that the
previous studies were conducted in very specific study
populations (predominantly female Hispanics or veterans
in the USA), this study evaluates measures of test perform-
ance of the Williams et al. single-item screener in com-
parison to PHQ-9 in a population-based sample of adults
from Germany. The aim of this study is to conclude on
the utility of this single item screener to screen for depres-
sion in the general population.
Methods
Study design and subjects
The data stem from the city of Augsburg (Bavaria,
Germany) and from surrounding districts covering about
600,000 inhabitants drawn from mixed urban and rural
areas whose demographic and socioeconomic characteris-
tics roughly reflect those of the average middle European
population in general. The present analysis investigates data
from the population-based KORA F3 survey conducted in
2004/05 within the framework of the ongoing KORA pro-
ject (Cooperative Health Research in the Augsburg Region,
Germany), a research platform for population-based health
research [23]. The KORA F3 survey is a follow-up survey
to the MONICA S3 survey conducted in 1994/95—at that
time one cooperative centre within the worldwide WHO
MONICA (Monitoring Trends and Determinants on Car-
diovascular Diseases) project investigating the general and
cardiovascular health of diverse populations. For the MON-
ICA S3 survey, a stratified random representative sample of
6481 eligible subjects was drawn in 1994/95 from the popu-
lation, of whom a total of 4856 subjects (response rate:
74.9%) participated in the S3 baseline survey. By the F3
follow-up study one decade later (2004/05), a total of 405
(8%) subjects had died. Furthermore, subjects were consid-
ered ineligible for inclusion in the F3 follow-up survey if
they lived too far outside the study region or were com-
pletely lost to follow-up (n = 222, 5%), or had demandeddeletion of their address data (n = 270, 6%). Of the re-
maining 3959 eligible subjects, 161 could not be contacted,
295 were unable to come because they were too ill, and 497
were not willing to participate, resulting in an interim total
of 3006 participants in the F3 follow-up survey (response
rate: 76% of S3 participants). Furthermore, additional ef-
forts were made to reach those 1300 eligible subjects from
the original S3 sampling frame who had not participated in
the S3 baseline survey. Thus, another 178 (14%) partici-
pated in the present KORA F3 study, for a total sample size
of 3184 (overall response rate: 49.12%). Written informed
consent was obtained from each study participant and the
study was approved by the ethics committee of the Bavarian
Medical Association.
Instruments
All participants underwent a standardized face-to face
interview including the Patient Health Questionnaire and
the single item screener and an extensive medical examin-
ation. The interviews were performed by experienced
study nurses at the KORA Study Centre, Augsburg. Before
start of the study, they received an extended training pro-
gram and were certified thereafter. All interviews were
taped and subjected to a routine quality assessment in the
KORA data centre to avoid bias. At study halftime, all in-
terviewers were recertified. Depression was assessed in an
interview version of the 9 item depression module of the
Patient Health Questionnaire (PHQ-9) [24]. Patients rate
the frequency of symptoms of depression over the past 2
weeks on an ordinal scale (0 = not at all, 1 = several days,
2 =more than half the days, 3 = nearly every day). The 9
items are based on the 9 DSM-IV criteria for the diagnosis
of depression. The total score ranges from 0 to 27. In
order to be congruent with the DSM-IV criteria, the algo-
rithm developed and validated by Spitzer et al. was used
for classification: “Major depressive disorder” was defined
as having at least five questions answered with “more than
half the time in the past two weeks”, of which at least one
of the first two questions (little interest in doing things,
feeling depressed) had to be included. Participants were
labelled to have “depressive mood” when 2 to 4 questions
were answered with “more than half the time in the past
two weeks”, also including one of the first two questions
of the PHQ-9 questionnaire [24]. PHQ-9 was used as ref-
erence standard in this study because it has been shown
to have a sensitivity of 88% and a specificity of 88% for
major depression compared with diagnostic SCID inter-
views [24] as well as concurrent validity, high internal con-
sistency, and test-retest reliability [25].
The single item screener “Have you been depressed or
sad most of the past year?” uses a yes/no response format
[11]. Based on a frequently used question for medical his-
tory taking, this single item question has been developed in
the context of a randomised controlled trial of case finding
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Hispanic and was recruited at family and internal medicine
clinics in the United States. Consecutive patients were
randomly assigned to be asked the single item screener,
to fill out the 20-item (CES-D), or to usual care. Corson
et al. reported a LR + of the single item screener of 6.77
and an area under the ROC of .83 (95% confidence inter-
val (CI) .79, .87) [20]. The single item screener was admin-
istered directly in advance to the PHQ-9.
Statistical analyses
Firstly, the distribution of socio-demographic and clinical
characteristics across the study sample was calculated for
description of the study population. Secondly, we calcu-
lated several measures of test performance of the single
item screener in comparison to the reference standard
PHQ-9. This was done for the PHQ-9 “depressive mood”
definition as well as for the “major depressive disorder”
definition based on a 2×2 table (see Table 1). Specifically,
we calculated the prevalence of persons with “depressive
mood” and of “major depressive disorder”. Sensitivity (the
proportion of persons having depression according to the
PHQ-9 who test positive in the single item screener), spe-
cificity (the proportion of persons without the disease ac-
cording to the PHQ-9 who test negative in the single item
screener), receiver operating characteristic (ROC) area,
the positive likelihood ratio (LR+, the probability of a per-
son who has the disease according to the PHQ-9 and tests
positive in the single item screener divided by the prob-
ability of a person who does not have the disease and tests
positive), the negative likelihood ratio (LR-, the probability
of a person who has the disease and tests negative divided
by the probability of a person who does not have the dis-
ease and tests negative), the positive predictive value (PPV,
the proportion of persons testing positive in the single
item screener who have the disease), and the negative pre-
dictive value (NPV, the proportion of persons testing
negative in the single item screener who do not have the
disease) of the single item screener in comparison withTable 1 2 × 2 table of the single item screener using the
“depressive mood” definition and the “major depressive
disorder” definition of the 9-item Patient Health
Questionnaire (PHQ-9) as reference standard
Single item screener Total
PHQ-9 “depressive mood” Positive Negative
Abnormal 406 475 881
Normal 130 2139 2269
PHQ-9 “major depressive disorder”
Abnormal 169 35 204
Normal 367 2579 2946
Total 536 2614 3150
PHQ-9: 9-item depression module of the Patient Health Questionnaire.either PHQ-9 depressive disorder definition were calcu-
lated, including 95% confidence intervals. The ROC is a
graphical plot of the fraction of true positives out of the
total actual positives (sensitivity) vs. the fraction of false
positives out of the total actual negatives (1-specificity), at
various threshold settings. The area under the ROC is a
measure for test accuracy with a value of 1 representing a
perfect test and an area of 0.5 representing a worthless
test. These analyses were repeated stratified for age group
(34–44, 45–54, 55–64, 65–74, 75–85 years) and gender
(female, male), two variables known to be linked with a
different prevalence of depressive disorders in the general
population [26]. Additionally, the proportion of false posi-
tive test results was calculated using the PHQ-9 “depressive
mood” definition. All analyses were done using STATA ver-
sion 11.0 (Stata Corporation, College Station, Texas, USA).
Results
Table 2 depicts the socio-demographic and clinical char-
acteristics of the study sample. The proportion of male
and female participants was almost equal with all age
groups included being adequately represented. 21.63% of
male participants and 33.93% of female participants were
categorised to have “depressive mood” according to the
established PHQ-9 definition. “Major depressive disorder”
was prevalent in 4.46% of men and in 8.37% of women.
The prevalence of depressive disorders of either definition
increased with advancing age.
The prevalence of “depressive mood” increased from
20% (95% CI 17–23.3) in persons aged 34-to 44 years to
34% (29–39.4) in persons older than 75 years. Sensitivity
of the single item screener was low across all age groups
and genders, though it increased from 37.5% (29.1-46.5) to
52.5% (43.2-61.6) with advancing age. Specificity was >90%
in all subgroups investigated, with very high values of >95%
in persons younger than 55 years and in males. An area
under the curve (AUC) of.702 (.685-.719) in the ROC ana-
lysis of the total sample was moderately good (Table 3).
An LR + of >10 indicates that the post-test probability
of having “depressive mood” is considerably increased.
LR+ > 10 have been detected in our analysis in the youn-
ger age groups and in the male study population, but
not in the higher age groups or in females, resulting in a
LR + of 8.04 (6.71-9.64) for the total sample. LR- indicate
the ability of the single item screener to decrease the post-
test probability of having “depressive mood”, the conven-
tional cut-point being LR- < .1. LR- in our analysis ranged
from 0.523 (.432-.632) to 0.809 (.555-.667) indicating no
reasonable decrease in post-test probability. PPVs corres-
pond to a probability of having “depressive mood” in the
presence of a positive single item screener of >70% in all
subgroups investigated. NPVs ranging from 77.8% (75.4-
80.1) to 86% (82.9-88.8) relate to fairly high probability to
be healthy when the single item response is negative
Table 2 Socio-demographic and clinical characteristics of the study sample
Characteristic Male Female Total
N (%) N (%) N (%)
All age groups 1,545 (48.52%) 1,639 (51.48%) 3,184 (100%)
34-44 years 320 (20.71%) 323 (19.71%) 643 (20.19%)
45-54 years 330 (21.36%) 404 (24.65%) 734 (23.05%)
55-64 years 372 (24.08%) 394 (24.04%) 766 (24.06%
65-74 years 323 (20.91%) 347 (21.17%) 670 (21.04%)
75-85 years 200 (12.94%) 171 (10.43%) 371 (11.65%)
Basic education 912 (59.22%) 968 (59.31%) 1880 (59.04%)
Diabetes mellitus 141 (9.16%) 117 (7.15%) 258 (8.84%)
Angina pectoris 112 (7.29%) 134 (8.20%) 246 (8.41%)
Previous hospitalisation due to myocardial infarction 58 (3.77%) 30 (1.83%) 88 (2.85%)
Intake of antidepressants 40 (2.60%) 101 (6.16%) 141 (4.64%)
PHQ-9 “depressive mood”, all age groups 330 (21.63%) 551 (33.93%) 881 (27.97%)
34-44 years 49 (15.41%) 79 (24.61%) 128 (20.03%)
45-54 years 57 (17.33%) 123 (30.60%) 180 (24.62%)
55-64 years 94 (25.41%) 146 (37.15%) 240 (31.45%)
65-74 years 78 (24.53%) 133 (38.66%) 211 (31.87%)
75-85 years 52 (27.23%) 70 (42.68%) 122 (34.37%)
PHQ-9 “major depressive disorder”, all age groups 68 (4.46%) 136 (8.37%) 204 (6.48%)
34-44 years 10 (3.14%) 14 (4.36%) 24 (3.76%)
45-54 years 14 (4.26%) 31 (7.71%) 45 (6.16%)
55-64 years 14 (3.78%) 32 (8.14%) 46 (6.03%)
65-74 years 13 (4.09%) 39 (11.34%) 52 (7.85%)
75-85 years 17 (8.90%) 20 (12.20%) 37 (10.42%)
PHQ-9: 9-item depression module of the Patient Health Questionnaire.
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gle item screener positive, but no diagnosis of “depressive
mood” in PHQ-9) was 130/2269, i.e. 5.7%, ranging from
3.5% in the 34–44 age group up to 8.9% in the 75–85 age
group.
When using the more conservative classification of
PHQ-9, 6.5% (5.6-7.4) in the total sample were identified
as having a “major depressive disorder” (3.8% (2.4-5.5) inTable 3 Prevalence and test performance of the single item s
9-item Patient Health Questionnaire (PHQ-9) as reference sta
Age group Prevalence Sensitivity Specifity ROC area
34-44 20 (17–23.3) 37.5 (29.1-46.5) 96.5 (94.5-97.9) .67 (.627-.71
45-54 25 (22–27.9) 46.1 (38.7-53.7) 95.5 (93.4-97) .708 (.67-.74
55-64 31 (28–34.9) 45.8 (39.4-52.4) 93.7 (91.3-95.6) .698 (.664-.7
65-74 32 (28–35.6) 47.9 (41–54.8) 92.7 (89.9-94.9) .703 .667-.73
75-85 34 (29–39.4) 52.5 (43.2-61.6) 91 (86.6-94.3) .717 (.669-.7
Female 34 (32–36.3) 48.8 (44.6-53.1) 92.3 (90.5-93.8) .705 (.683-.7
Male 22 (20–23.8) 41.5 (36.1-47) 96.1 (94.8-97.1) .688 (.661-.7
Total 28 (26–29.6) 46.1 (42.8-49.4) 94.3 (93.2-95.2) .702 (.685-.7
ROC: receiver operating characteristic; LR+: positive likelihood ratio; LR-: negative likthe 34–44 age group, N = 24; 10% (7.4-14.1) in the >75
age group, N = 37). In comparison to this PHQ-9 defin-
ition, the single item screener demonstrated fairly good
sensitivity with 75% (53.3-90.2) in the low-prevalence age
group of 34–44 up to 86.5% (71.2-95.5) in those >65 years
of age. Specificity of 87.5% (86.3-88.7) in the total sample
was also fairly good with comparably low specificity in
those subgroups with comparably high sensitivity and vicecreener using the “depressive mood” definition of the
ndard (95% confidence interval)
LR+ LR- PPV NPV
3) 10.6 (6.42-17.7) .648 (.556-.742) 72.7 (60.4-83) 86 (82.9-88.8)
5) 10.2 (6.72-15.4) .565 (.493-.647) 76.9 (67.8-84.4) 84.4 (81.3-87.2)
31) 7.26 (5.08-10.4) .578 (.514-.651) 76.9 (69.1-83.6) 79 (75.6-82.2)
9) 6.54 (4.58-9.35) .562 (.493-.642) 75.4 (67.2-82.4) 79.2 (75.4-82.6)
65) 5.82 3.74-9.05) .523 (.432-.632) 75.3 (64.7-84) 78.5 (73.1-83.3)
28) 6.31 (5.05-7.89) .555 (.51-.603) 76.4 (71.6-80.8) 77.8 (75.4-80.1)
15 10.6 (7.76-14.4) .809 (.555-.667) 74.5 (67.5-80.6) 85.6 (83.6-87.5)
19) 8.04 (6.71-9.64) .572 (.538-.608) 75.7 (71.9-79.3) 81.8 (80.3-83.3)
elihood ratio; PPV: positive predictive value; NPV: negative predictive value.
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group and 83.3% (78.8-87.3) in the >75 age group). As
compared to the “depressive mood” definition, using the
“major depressive disorder” definition resulted in a signifi-
cantly higher ROC area of .852 (.825-.879) (Table 4).
The single item screener is not useful for ruling in major
depressive disorder, as the LR + in the total sample is 6.65
(5.93-7.46) and for most subgroups far away from >10.
The ability of ruling out major depressive disorder is
much better with a LR- of .196 (.145-.265) in the total
sample. However, in none of the subgroups investigated,
the LR- was < .1. Given the low prevalence of major de-
pressive disorder (according to PHQ-9), the PPVs and
NPVs as shown in Table 4 must be interpreted with care,
as a prevalence of >15% is considered to be adequate for
this type of analysis. Albeit, PPVs of about 30% indicate a
quite low probability of having major depressive disorder
in the presence of a positive single item screener (resulting
a high number of false positives), whereas it is almost sure
that a person does not have a major depressive disorder in
the presence of a negative test result (NPV in the total
sample 98.7% (98.1-99.1)).
Discussion
Interpreting the clinical meaning of the test result of a
simple yes/no single item question (“Have you been de-
pressed or sad most of the past year?”) in comparison to
the 9-item PHQ instrument is complex: In the presence
of a positive test result, the likelihood of the person having
a clinically relevant depressive disorder is considerably in-
creased (LR + 8.04 in comparison to PHQ-9 “depressive
mood”, LR + 6.65 in comparison to PHQ-9 “major depres-
sive disorder”). A person presenting with a positive single
item screener would therefore be in need for a more de-
tailed evaluation of depressive symptoms. In the presence
of a negative test result, a major depressive disorder is rela-
tively unlikely (LR- 0.196 in comparison to PHQ-9 “major
depressive disorder”), though the presence of a major de-
pressive disorder cannot completely excluded. However, a
negative test result does only minimally decrease theTable 4 Prevalence and test performance of the single item s
of the 9-item Patient Health Questionnaire (PHQ-9) as referen
Age group Prevalence Sensitivity Specifity ROC-area
34-44 3.8 (2.4-5.5) 75 (53.3-90.2) 92.2 (89.8-94.2) .836 (.747-.92
45-54 6.2 (4.5-8.2) 86.7 (73.2-94.9) 89.9 (87.2-92.1) .883 (.832-.93
55-64 6 (4.4-8.0) 76.1 (61.2-87.4) 84.9 (82.1-87.5) .805 (.741-.86
65-74 7.9 (5.9-10.2) 86.5 (74.2-94.4) 85.4 (82.4-88.1) .86 (.811-.90
75-85 10 (7.4-14.1) 86.5 (71.2-95.5) 83.3 (78.8-87.3) .849 (.79-.90
Female 8.4 (7.1-9.8) 81.6 (74.1-87.7) 83.8 81.8-85.6) .827 (.973-.86
Male 4.5 (3.5 -5.6) 85.3 (74.6-92.7) 91.4 (89.8-92.8) .883 (.84-.92
Total 6.5 (5.6-7.4) 82.8 (77–87.7) 87.5 (86.3-88.7) .852 (.825-.87
ROC: receiver operating characteristic; LR+: positive likelihood ratio; LR-: negative liklikelihood of a person having depressive mood (LR- 0.572
in comparison to PHQ-9 “depressive mood”). As a result
of the varying prevalence of depressive disorders across
age groups and between females and males, we detected
differences in test performance measures across these
strata. However, the differences were not clear enough to
recommend the single item for specific use in certain
groups of patients.
When associating this study with previous research,
our results for sensitivity (83% in comparison with PHQ-9
“major depressive disorder”) are comparable with Williams
et al. [11] (85%) and slightly higher than those of Corson
et al. (78%) [20]. With respect to specificity, the present
study (88%) and the results of Corson et al. (88%) are con-
cordant, both done in comparison with PHQ-9 “major
depressive disorder”. However, when Williams et al. inves-
tigated the single item screener in comparison to SCID in-
terviews specificity was considerably lower (66%). Given
the fact that the PHQ-9 has been shown to have a specifi-
city of 80-90% in comparison to SCID interviews, [24] the
previous findings seem plausible.
However, poor specificity as compared to the gold stand-
ard translates into high rates of false-positive test results.
There is a vivid discussion on whether current criteria for
clinical diagnosis of depression are medicalising sadness
[27] or whether - in contrary - there are still many people
missing on life saving treatment [28]. The debate also in-
cludes whether screening for depression increases over
diagnosis or whether it is an effective public health meas-
ure [14,29]. We did not detect substantial differences in
the rates of false-positives between the single item screener
and PHQ-9 (5.7% of single item test results in comparison
to PHQ-9 “depressive mood”). However, as stated above,
we did not compare against the gold standard, and there is
a considerable amount of false-positives when applying the
PHQ-9 which we were not able to detect in the present
study [22,24,25].
In comparison to PHQ-9, the main limitation of the
single item screener is the relatively low ability to detect
less-than-severe depressive disorders. Therefore, the utilitycreener using the “major depressive disorder” definition
ce standard (95% confidence interval)
LR+ LR- PPV NPV
5) 9.61 (6.73-13.7) .271 (.136-.542) 27.3 (17–39.6) 99 (97.7-99.6)
5) 8.62 (6.7-11.1) .148 (.070-.312) 36.1 (27.1-45.9) 99 (97.9-99.6)
9) 5.05 (3.98-6.41) .282 (.168-.472) 24.5 (17.7-32.4) 98.2 (96.8-99.1)
9) 5.93 (4.76-7.39) .158 (.0791-.314) 33.6 (25.7-42.2) 98.7 (97.3-99.5)
9) 5.19 (3.93-6.84) .162 (.0717-.367) 37.6 (27.4-48.8) 98.1 (95.7-99.4)
1) 5.04 (4.38-5.8) .219 (.154-.313) 31.5 (26.7-36.7) 98 (97.1-98.7)
6) 9.87 (8.13-12) .161 (.0908-.285) 31.5 (24.9-38.8) 99.3 (98.6-99.6)
9) 6.65 (5.93-7.46) .196 (.145-.265) 31.5 (27.6-35.7) 98.7 (98.1-99.1)
elihood ratio; PPV: positive predictive value; NPV: negative predictive value.
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might be used as a first step of a screening procedure in
combination with other, more detailed assessment instru-
ments. For example, such a two-step screening procedures
has been recommended by the American Heart Associ-
ation for patients with coronary heart disease [30]. Elderon
et al. evaluated this recommendation using the PHQ-2
and the PHQ-9 sequentially and found this procedure to
be highly specific, poorly sensitive, but predictive of poor
coronary outcomes [31]. Similar two-step screening proce-
dures may also be applied in other settings or other patient
populations.
In contrast to clinical settings, the single item screener
may be helpful for selection of specific patient populations
if the absence of a depressive disorder (negative test result)
or the presence of a major depressive disorder (positive test
result) is selection criterion and if space, time or resources
for more comprehensive questionnaires are limited.
When interpreting this study, several limitations need
to be considered. This is a secondary analysis of data of
the large, population-based KORA cohort study which has
not specifically been designed for the research question ad-
dressed in the present manuscript. SCID interviews which
were not available in this project are considered to be the
gold standard for diagnosing depressive disorders in re-
search contexts. However, we used PHQ-9 as the reference
standard which has been shown to have good concordance
with clinical diagnosis of depression [32]. Additionally, all
participants lived in Bavaria so that there may be cultural
differences in the prevalence and diagnostic identification
of depressive disorders as compared to other countries.
Moreover, some of the persons who were eligible for the
study were not willing to participate (S3 baseline survey re-
sponse rate = 74.9%), and some of those who participated
at baseline, had dropped out for the F3 follow-up (F3
follow-up survey response rate: 76% of S3 participants) so
that selection bias cannot be excluded. However, the
demographic and socioeconomic characteristics of the
underlying population roughly reflect those of the average
middle European population in general [23]. In addition,
the reader should keep in mind that the PHQ-9 assesses
depressive symptoms within the last 2 weeks, whereas the
single item screener inquires about the past year. So, the
PHQ-9 is in line with a diagnosis of depression according
to the DSM-IV or DSM-V criteria, when the single item
screener includes a global assessment of a much longer
interval but does not inquire detailed aspects of depression.
Another limitation is that reliability of the single item
screener, e.g. test-retest performance has not been evalu-
ated so far and should be included in future research.
Conclusions
In comparison to PHQ-9, the single item screener pro-
posed by Williams et al. is able to moderately decreasethe likelihood of major depressive disorders and to identify
populations that should undergo additional, more detailed
depression screening measures. However, in comparison
to PHQ-9 the single item screener has a low ability to de-
tect less-than-severe depressive disorders and can there-
fore not be recommended for routine use as a screening
tool in clinical practice.
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